ACQUIREDT+7
Corcept Therapeutics Inc · NASDAQ
+413 sh · $3.4K
Filed 5 Oct 2026SEC Form 4view source
- ACQUIREDT+7
Corcept Therapeutics Inc · NASDAQ
+24,587 sh · $203.3K
Filed 5 Oct 2026SEC Form 4view source - REDUCEDT+7
Corcept Therapeutics Inc · NASDAQ
−15,843 sh · $1.8M
Filed 5 Oct 2026SEC Form 4view source - REDUCEDT+7
Corcept Therapeutics Inc · NASDAQ
−8,744 sh · $1.0M
Filed 5 Oct 2026SEC Form 4view source - REDUCEDT+7
Corcept Therapeutics Inc · NASDAQ
−413 sh · $47.7K
Filed 5 Oct 2026SEC Form 4view source - REDUCEDStale
Corcept Therapeutics Inc · NASDAQ
−11,730 sh · $1.3M
Filed 3 Sept 2026SEC Form 4view source - REDUCEDStale
Corcept Therapeutics Inc · NASDAQ
−10,989 sh · $1.3M
Filed 3 Sept 2026SEC Form 4view source - ACQUIREDStale
Corcept Therapeutics Inc · NASDAQ
+25,000 sh · $206.8K
Filed 3 Sept 2026SEC Form 4view source - ACQUIREDStale
Corcept Therapeutics Inc · NASDAQ
+150 sh
Filed 3 Sept 2026SEC Form 4view source - REDUCEDStale
Corcept Therapeutics Inc · NASDAQ
−117 sh · $13.3K
Filed 3 Sept 2026SEC Form 4view source - ACQUIREDStale
Corcept Therapeutics Inc · NASDAQ
+150 sh · $17.0K
Filed 3 Sept 2026SEC Form 4view source - REDUCEDStale
Corcept Therapeutics Inc · NASDAQ
−2,281 sh · $263.7K
Filed 3 Sept 2026SEC Form 4view source - REDUCEDStale
Corcept Therapeutics Inc · NASDAQ
−5,870 sh · $740.0K
Filed 27 Aug 2026SEC Form 4view source - ACQUIREDStale
Corcept Therapeutics Inc · NASDAQ
+30,955 sh · $351.3K
Filed 27 Aug 2026SEC Form 4view source - REDUCEDStale
Corcept Therapeutics Inc · NASDAQ
−25,085 sh · $3.1M
Filed 27 Aug 2026SEC Form 4view source